Kura Oncology to Report Third Quarter 2024 Financial Results

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) announced it will release its third quarter 2024 financial results after U.S. market close on Thursday, November 7, 2024. The company will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day, featuring management's discussion of financial results and a corporate update. Investors can access the call via phone or watch the webcast through the company's website.

10/31/2024 - 07:30 AM

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2024 financial results after the close of U.S. financial markets on Thursday, November 7, 2024. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (800) 225-9448 for domestic callers and (203) 518-9708 for international callers and entering the conference ID: KURAQ3. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Kura is evaluating KO-2806, a next-generation farnesyl transferase inhibitor (FTI), in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.

Contacts

Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com

Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com

FAQ

When will Kura Oncology (KURA) release Q3 2024 earnings?

Kura Oncology will release its third quarter 2024 financial results after U.S. market close on Thursday, November 7, 2024.

What time is Kura Oncology's (KURA) Q3 2024 earnings call?

Kura Oncology's Q3 2024 earnings conference call and webcast will take place at 4:30 p.m. ET / 1:30 p.m. PT on Thursday, November 7, 2024.

How can investors access Kura Oncology's (KURA) Q3 2024 earnings call?

Investors can access the call by dialing (800) 225-9448 (domestic) or (203) 518-9708 (international) with conference ID: KURAQ3, or watch the webcast through the company's investor relations website.